Hematologic Malignancies

FDA Approves Isa-VRd for Newly Diagnosed Myeloma

The FDA approved the quadruplet therapy Isa-VRd for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

FDA Approves Isa-VRd for Newly Diagnosed Myeloma

The FDA approved the quadruplet therapy Isa-VRd for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Daniel A. Ermann, MD; Robert A. Figlin, MD, FACP

FDA Approvals in CLL Set up “Difficult Choice”

Podcast

Daniel A. Ermann, MD, and Robert A. Figlin, MD, discuss how two new FDA approvals in CLL set up “a difficult choice” and what to consider when deciding.

Daniel A. Ermann, MD; Robert A. Figlin, MD, FACP

FDA Approvals in CLL Set up “Difficult Choice”

Podcast

Daniel A. Ermann, MD, and Robert A. Figlin, MD, discuss how two new FDA approvals in CLL set up “a difficult choice” and what to consider when deciding.

FDA Approves Epcoritamab in Follicular Lymphoma

The FDA granted accelerated approval to epcoritamab for adults with relapsed or refractory follicular lymphoma after at least two lines of therapy.

FDA Approves Epcoritamab in Follicular Lymphoma

The FDA granted accelerated approval to epcoritamab for adults with relapsed or refractory follicular lymphoma after at least two lines of therapy.

LMWH Did Not Prevent Thromboembolism in ALL

Low-molecular-weight heparin did not prevent thrombosis in adult patients with ALL; there was an unexpected signal that it may raise the risk in some patients.

LMWH Did Not Prevent Thromboembolism in ALL

Low-molecular-weight heparin did not prevent thrombosis in adult patients with ALL; there was an unexpected signal that it may raise the risk in some patients.

Upfront Acalabrutinib Plus BR Ups PFS in MCL

Acalabrutinib plus bendamustine/rituximab improves progression-free survival in older patients with MCL, but some experts remain skeptical of the benefit.

Upfront Acalabrutinib Plus BR Ups PFS in MCL

Acalabrutinib plus bendamustine/rituximab improves progression-free survival in older patients with MCL, but some experts remain skeptical of the benefit.

Not All TP53 Mutations Equal in CLL, Data Suggest

TP53 mutation status is a commonly used biomarker for high-risk disease in chronic lymphocytic leukemia, but some variants may be less dangerous than others.

Not All TP53 Mutations Equal in CLL, Data Suggest

TP53 mutation status is a commonly used biomarker for high-risk disease in chronic lymphocytic leukemia, but some variants may be less dangerous than others.

Glofitamab Plus Chemo Improves Survival in DLBCL

Glofitamab plus chemo doubles overall survival in patients with diffuse large B-cell lymphoma compared with rituximab plus chemo, researchers at EHA reported.

Glofitamab Plus Chemo Improves Survival in DLBCL

Glofitamab plus chemo doubles overall survival in patients with diffuse large B-cell lymphoma compared with rituximab plus chemo, researchers at EHA reported.

FDA Oks Blinatumomab Consolidation for ALL

Rabiya S. Tuma, PhD

The FDA approved the use of blinatumomab for consolidation therapy for some adult and pediatric patients with B-cell precursor ALL.

FDA Oks Blinatumomab Consolidation for ALL

Rabiya S. Tuma, PhD

The FDA approved the use of blinatumomab for consolidation therapy for some adult and pediatric patients with B-cell precursor ALL.

Isa-VRd New Standard for Multiple Myeloma

Treatment with the CD38-targeted isatuximab plus VRd significantly improves PFS in newly diagnosed multiple myeloma, according to results of the IMROZ trial.

Isa-VRd New Standard for Multiple Myeloma

Treatment with the CD38-targeted isatuximab plus VRd significantly improves PFS in newly diagnosed multiple myeloma, according to results of the IMROZ trial.

William G. Wierda, MD, PhD

Ibrutinib/Venetoclax in CLL Maintains PFS Benefit

Long-term follow-up data from the CAPTIVATE study show continued PFS benefit with fixed-duration ibrutinib plus venetoclax in high-risk patients with CLL.

William G. Wierda, MD, PhD

Ibrutinib/Venetoclax in CLL Maintains PFS Benefit

Myelodysplastic Syndromes (MDS)

Long-term follow-up data from the CAPTIVATE study show continued PFS benefit with fixed-duration ibrutinib plus venetoclax in high-risk patients with CLL.

FDA Approves Imetelstat in Some MDS

Myelodysplastic Syndromes (MDS)

The FDA approved imetelstat for adults with low- to intermediate-risk myelodysplastic syndromes with transfusion-dependent anemia.

FDA Approves Imetelstat in Some MDS

The FDA approved imetelstat for adults with low- to intermediate-risk myelodysplastic syndromes with transfusion-dependent anemia.

“Million-Dollar Question” in Multiple Myeloma

Yi Lin, MD, PhD

“How to select the treatment for that novel immunotherapy is the million-dollar question” in multiple myeloma care, says Yi Lin, MD.

“Million-Dollar Question” in Multiple Myeloma

Yi Lin, MD, PhD